TABLE 2.
ExsA | % of probe shifted in the presence of the indicated N-hydroxybenzimidazolea |
|||||
---|---|---|---|---|---|---|
4816 | 5330 | 5631 | 5707 | 5784 | 5816 | |
Wild type | 34 ± 4 | 60 ± 4 | 8 ± 5 | 3 ± 2 | 7 ± 4 | 7 ± 5 |
H180E mutant | 45 ± 4 | 50 ± 5 | 11 ± 1 | 4 ± 1 | 9 ± 4 | 32 ± 5* |
N183E mutant | 40 ± 2 | 59 ± 3 | 15 ± 2 | 51 ± 6* | 45 ± 8* | 41 ± 4* |
I217E mutant | 26 ± 9 | 71 ± 10 | 2 ± 1 | 35 ± 4* | 69 ± 1* | 2 ± 1 |
E184A mutant | 3 ± 1* | 59 ± 6 | 7 ± 1 | 33 ± 4* | 28 ± 4* | 5 ± 4 |
K186A mutant | 55 ± 5 | 76 ± 2 | 15 ± 3 | 30 ± 7* | 16 ± 3 | 42 ± 3* |
P213A mutant | 13 ± 6 | 59 ± 6 | 3 ± 1 | 2 ± 1 | 2 ± 1 | 3 ± 1 |
R214A mutant | 2 ± 1* | 39 ± 1 | 2 ± 1 | 3 ± 1 | 38 ± 1* | 2 ± 1 |
M241A mutant | 63 ± 6* | 51 ± 10 | 2 ± 1 | 6 ± 4 | 71 ± 4* | 63 ± 11* |
S246A mutant | 28 ± 4 | 72 ± 9 | 2 ± 1 | 13 ± 5* | 25 ± 7 | 29 ± 5* |
The N-hydroxybenzimidazoles were used at a concentration of 125 μM. Each horizontal data set represents the percent of the PexsC promoter probe shifted following treatment with each N-hydroxybenzimidazole relative to an untreated control normalized to 100%. *, P < 0.01.